AnaMar Overview

  • Founded
  • 1998
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 8
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 4

AnaMar General Information

Description

Developer of novel therapeutic drugs intended to treat debilitating inflammation and pain. The company's drugs target the extracellular matrix producing myofibroblast to treat systemic sclerosis, enabling physicians to treat their patients in an enhanced way.

Contact Information

Website
www.anamar.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Parent Company
Koncentra Holding
Primary Office
  • Medicon Village
  • Scheelevagen 2
  • 223 81 Lund
  • Sweden
+46 046-275 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AnaMar Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AnaMar‘s full profile, request access.

Request a free trial

AnaMar Patents

AnaMar Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3753924-A1 New tricyclic 5-ht2 antagonists Pending 18-Jun-2019 0000000000 0
JP-2018522829-A Novel 5-ht2 antagonists Granted 22-Jun-2015 0000000000
AU-2016282325-B2 Novel 5-ht2 antagonists Active 22-Jun-2015 0000000000
CA-2988033-A1 1-amidino-3-aryl-2-pyrazoline derivatives as 5-ht2 antagonists Granted 22-Jun-2015 0000000000
CA-2988033-C 1-amidino-3-aryl-2-pyrazoline derivatives as 5-ht2 antagonists Active 22-Jun-2015 C07D231/06

AnaMar Executive Team (5)

Name Title Board Seat Contact Info
Ulf Ljungberg Ph.D Chief Executive Officer
Denise Goode Vice President, Business Development & Board Member
Gunilla Ekstrom Ph.D Vice President, Research & Development
Göran Tornling MD Chief Medical Officer
You’re viewing 4 of 5 executive team members. Get the full list »

AnaMar Board Members (6)

Name Representing Role Since
000000 000000 00.0 Self Board Member 000 0000
000000 00000 AnaMar Vice President, Business Development & Board Member 000 0000
0000000 00000000 Self Chairman 000 0000
You’re viewing 3 of 6 board members. Get the full list »

AnaMar Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AnaMar Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AnaMar‘s full profile, request access.

Request a free trial